The reiteration of an Overweight rating and maintenance of a $30 price target by Cantor Fitzgerald analyst Li Watsek indicates a positive outlook for Kura Oncology. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.